Actively Recruiting
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Led by University of California, Davis · Updated on 2025-12-05
75
Participants Needed
1
Research Sites
604 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.
CONDITIONS
Official Title
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.
You will not qualify if you...
- Age less than 18 years or greater than 65 years
- Patients planned for nonoperative management who later undergo embolization or splenectomy will be withdrawn from the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, Davis Medical Center
Sacramento, California, United States, 95817
Actively Recruiting
Research Team
D
David V Shatz, MD
CONTACT
A
Anthony Calabro, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here